All articles by Sally Turner
Sally Turner
Sally Turner is a UK-based health journalist who has written on a diverse range of topics including the microbiome, gene therapy, the patient relationship, and pharmaceutical pollution. She is particularly interested in pharmaceutical advances related to sexual health, women's healthcare, autoimmune diseases, and chronic pain.
Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023
Pharmaceutical Technology outlines some of the biggest US Food and Drug Administration (FDA) drug approvals announced in 2023 that are set to make an impact in the coming years.
Childproof packaging: How things are changing for consumer drugs
New sustainable child-resistant packaging technologies need to be prioritised to avoid drug recalls.
Cancer treatment uncertainty: European nations struggle with drug shortages
Experts in Europe detail the challenge with current cancer drug shortages and how regulators are trying to abate the scarcity.
Robotics: Transforming cell and gene therapy manufacturing
Several companies are developing robotics to automate cell and gene therapy manufacturing, but some challenges persist.
From Europe to Latin America: Driving access to affordable biosimilars
Act4Biosimilars, an international advocacy organisation is pushing for country-specific initiatives to increase biosimilar usage.
Clinics ration supplies as cancer drug shortages proliferate
While drug shortages have been a major cause for concern over the past few years, medications to treat cancer are in particularly short supply.
Cybersecurity in pharma: Securing the future
Over the past decade, several pharma and medical device companies and healthcare facilities have been at the receiving end of cyberattacks.
The emergence of tranq amidst the fentanyl crisis
On National fentanyl awareness day, we take a look at xylazine, also known as tranq, which is increasingly being detected in drug overdose cases across the US.
Pathbreakers: The journey of first generics
In 2022, the US FDA approved 106 first generics, but access to these cost-saving drugs still remains a challenge.
Primate models in pharma: What the future holds
Federal agencies in the US, Europe, and elsewhere are regulating the use of primate models in the backdrop of recent controversies.